TORONTO, March 19, 2014 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting").
The amended proxy is posted on SEDAR and the EDGAR system of the U.S. Securities and Exchange Commission, together with a letter sent to registered shareholders describing the reason for the amended proxy, that relates solely to the third item of business listed in the proxy and to be voted on at the Meeting (the "Amended Proxy Letter"). The Company has confirmed that all votes cast as "Withhold from Voting" on this third item of business in the original proxy will be voted "Against" that matter. If registered shareholders of the Company would like to change the manner in which they have voted via proxy for matters to be voted on at the Meeting or have not yet voted and would like to do so, they should follow the instructions in the Amended Proxy Letter. Beneficial shareholders of the Company who hold their shares through their brokers, intermediaries, trustees or other nominees should contact their broker, intermediary, trustee or nominee if they would like to change the manner in which they have issued instructions for voting at the Meeting or have not issued such instructions and would like to do so.
All proxies must be received prior to 10:30 a.m. (Toronto time) on the business day preceding the date of the Meeting or any adjournment thereof.About Intellipharmaceutics Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals. Based on this technology platform, Intellipharmaceutics has developed several drug delivery systems and a pipeline of products (our dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths which recently received final FDA approval) and product candidates in various stages of development, including Abbreviated New Drug Applications ("ANDAs") filed with the FDA in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts